BGLC
BioNexus Gene Lab Corp.4.1200
-0.0200-0.48%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.74MP/E (TTM)
-Basic EPS (TTM)
-1.28Dividend Yield
0%Recent Filings
8-K
Chemrex board restructured
BioNexus Gene Lab Corp. completed a governance restructuring at wholly owned subsidiary Chemrex on February 23, 2026, streamlining its board to Chairman Matthew L. Barsing and Director Angeline Chong. This aligns Chemrex oversight with parent-level standards amid evaluations of biotech expansion under a July 2025 capital framework. No commitments yet. Streamlined board sharpens execution.
8-K
VitaGuard™ deployment launches
BioNexus Gene Lab Corp. kicked off its 2026 regional deployment of the VitaGuard™ MRD platform on January 28, targeting Southeast Asia's medical hubs to integrate affordable cancer monitoring into routine workflows. Leveraging Fidelion Diagnostics for IP and commercialization outside Greater China, the company eyes high-frequency data for AI-oncology tools. Deployment starts 2026. Risks include regulatory delays and adoption hurdles.
8-K
Annual meeting approvals passed
BioNexus Gene Lab Corp. held its 2025 Annual Meeting on December 24, 2025, electing Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, and Chee Keong Yap as directors with overwhelming support—over 971K votes for each. Stockholders approved the 2025 Equity Incentive Plan (967K for), ratified JP Centurion & Partners PLT as auditors, and backed the adjournment proposal. Governance locked in.
8-K
Chemrex directors resign suddenly
BioNexus Gene Lab received resignations from four Chemrex directors—Mr. Too Kam Tham, Mr. Liong Tai Tan, Mr. Wei Foong Lim, and Mr. Kuan Yew Tan—on December 19, 2025, amid an ongoing governance review and CDMO expansion evaluation. Resignations hit during board reconstitution; Barsing now chairs. Company assesses impacts, no conclusions yet.
8-K
Secures $500M facility, VitaGuard license
BioNexus inked two pacts on November 28: a $500M equity line with ARC, committing up to that over 36 months at 3-3.5% VWAP discounts (issued 175,000 commitment shares), and an exclusive Southeast Asia license for Fidelion's VitaGuard MRD platform ($2M fee in 24 installments, $500K reagent buy). ARC owns 7.4%; Fidelion 16.6% post 392K-share swap. Funds commercialization. Big capital firepower.
IPO
Employees
Sector
Industry
BCPC
Balchem Corporation
157.10-1.61
BIOF
Blue Biofuels Inc.
0.17-0.01
BON
Bon Natural Life Limited
1.79+0.04
BSLK
Bolt Projects Holdings, Inc.
1.81-0.01
KBLB
Kraig Biocraft Laboratories, In
0.09+0.00
LOOP
Loop Industries, Inc.
0.92-0.04
LYB
LyondellBasell Industries NV
42.98-0.36
SINC
Sincerity Applied Materials Hol
7.86-0.04
TSE
Trinseo PLC
0.48-0.07
WLK
Westlake Corporation
73.34-0.29